医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

GoodFriend Offers Discount on 2-Way Full-Body Massage Mat for Customer Appreciation Event

2023年10月24日 PM10:00
このエントリーをはてなブックマークに追加


 

ULSAN, South Korea

GoodFriend, a massager brand, extends the discount price on the 2-way full-body massage mat, a stretching massager, to thank customers for the complete sale of the product launched in April 2023.

GoodFriend released the “Shin Suji Sleep Science Full Body Stretching Massage Mat (heated),” a 1.6m-long massage mat with stretching and massaging functions that can be used from both front and rear sides. It is 40cm longer than the previous model and has six additional air cells to massage the calves (thighs). A new feature allows you to massage your sides by lying on the mat in the opposite direction. A total of 28 powerful air cells cover your entire body from the head through the back, waist, hips, and pelvis to the calves, providing intensive care for each part of the body.

GoodFriend representative Wohyun Sun said, “Using our internally developed technology, we created the 2-way full-body stretching massage mat to help people of all ages and fitness levels correct their posture. The mat is 40cm longer than the previous model for greater comfort, and it hugs the body tightly down to the calves, helping users stretch in stability and comfort using various modes.”

GoodFriend is giving away 30 devices as a thank-you event for the complete sale and as a social contribution activity.

For more information about GoodFriend or to purchase products, please visit its website: https://goodfriend3819.modoo.at/

View source version on businesswire.com: https://www.businesswire.com/news/home/20231024380080/en/

CONTACT

EDL ENTERPRISE for GoodFriend

Sujin Lee

lsj@edl.co.kr

同じカテゴリーの記事 

  • Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
  • Huonslab Announces Positive Results from In Vivo comparative PK study of Trastuzumab/HyDIFFUZETM compared with marketed rHuPH20 co-formulation with Trastuzumab
  • Rapid Medical™、TIGERTRIEVER™13を用いたDISTALS臨床試験の中間安全性解析で、中血管閉塞の安全性の懸念がないことを報告
  • Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
  • JCR Pharmaceuticals’ Data Presentations at SSIEM Annual Symposium 2024 Highlight Investigational Treatments for Lysosomal Storage Disorders